172 related articles for article (PubMed ID: 31971005)
1. Pharmacokinetics of Trastuzumab After Subcutaneous and Intravenous Administration in Obese Patients.
González García J; Gutiérrez Nicolás F; Ramos Díaz R; Nazco Casariego GJ; Viña Romero MM; Llabres Martinez M; Llanos Muñoz M; Batista López JN; Jiménez Sosa A; Ceballos Lenza I; Cruz Jurado J
Ann Pharmacother; 2020 Aug; 54(8):775-779. PubMed ID: 31971005
[No Abstract] [Full Text] [Related]
2. Is weight-based IV dosing of trastuzumab preferable to SC fixed-dose in some patients? A systematic scoping review.
Kolberg HC; Jackisch C; Hurvitz SA; Winstone J; Barham H; Hanes V; Courmier D
Breast; 2021 Jun; 57():95-103. PubMed ID: 33799233
[TBL] [Abstract][Full Text] [Related]
3. Influence of Anthropometric Characteristics in Patients With Her2-Positive Breast Cancer on Initial Plasma Concentrations of Trastuzumab.
González García J; Gutiérrez Nicolás F; Nazco Casariego GJ; Batista López JN; Ceballos Lenza I; Ramos Díaz R; Llabrés Martínez M
Ann Pharmacother; 2017 Nov; 51(11):976-980. PubMed ID: 28643558
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit.
Tjalma WAA; Van den Mooter T; Mertens T; Bastiaens V; Huizing MT; Papadimitriou K
Eur J Obstet Gynecol Reprod Biol; 2018 Feb; 221():46-51. PubMed ID: 29245056
[TBL] [Abstract][Full Text] [Related]
5. Use of subcutaneous and intravenous trastuzumab: real-world experience from three hospitals in Sweden.
Valachis A; Sundqvist M; Carlsson L; Li B; Chiesa F; Uhde M; Sanglier T
Future Oncol; 2019 Aug; 15(23):2733-2741. PubMed ID: 31306041
[No Abstract] [Full Text] [Related]
6. Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancer.
Quartino AL; Hillenbach C; Li J; Li H; Wada RD; Visich J; Li C; Heinzmann D; Jin JY; Lum BL
Cancer Chemother Pharmacol; 2016 Jan; 77(1):77-88. PubMed ID: 26645407
[TBL] [Abstract][Full Text] [Related]
7. Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer.
Olsen J; Jensen KF; Olesen DS; Knoop A
J Comp Eff Res; 2018 May; 7(5):411-419. PubMed ID: 29199854
[TBL] [Abstract][Full Text] [Related]
8. Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.
Kirschbrown WP; Wynne C; Kågedal M; Wada R; Li H; Wang B; Nijem I; Badovinac Crnjevic T; Gasser H; Heeson S; Eng-Wong J; Garg A
J Clin Pharmacol; 2019 May; 59(5):702-716. PubMed ID: 30570763
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab/Hyaluronidase-oysk: A New Option for Patients With HER2-Positive Breast Cancer.
Duco MR; Murdock JL; Reeves DJ
Ann Pharmacother; 2020 Mar; 54(3):254-261. PubMed ID: 31595774
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.
Pivot X; Verma S; Fallowfield L; Müller V; Lichinitser M; Jenkins V; Sánchez Muñoz A; Machackova Z; Osborne S; Gligorov J;
Eur J Cancer; 2017 Nov; 86():82-90. PubMed ID: 28963915
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer.
Denys H; Martinez-Mena CL; Martens MT; D'Hondt RG; Graas ML; Evron E; Fried G; Ben-Baruch NE; Vulsteke C; Van Steenberghe MM
Breast Cancer Res Treat; 2020 May; 181(1):97-105. PubMed ID: 32240454
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer.
Heo YA; Syed YY
Target Oncol; 2019 Dec; 14(6):749-758. PubMed ID: 31686307
[TBL] [Abstract][Full Text] [Related]
13. Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).
Ciruelos EM; Montaño A; Rodríguez CA; González-Flores E; Lluch A; Garrigós L; Quiroga V; Antón A; Malón D; Chacón JI; Velasco M; Gonzalez-Cortijo L; Jolis L; Echarri MJ; Muñoz M; Pascual T; Amigo Y; Casas M; Carrasco E; Casas A
Eur J Cancer Care (Engl); 2020 Jul; 29(4):e13253. PubMed ID: 32578279
[TBL] [Abstract][Full Text] [Related]
14. Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients.
Elsamany S; Elsisi GH; Hassanin F; Jafal M
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):511-518. PubMed ID: 33275459
[No Abstract] [Full Text] [Related]
15. Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland.
O'Brien GL; O'Mahony C; Cooke K; Kinneally A; Sinnott SJ; Walshe V; Mulcahy M; Byrne S
Clin Breast Cancer; 2019 Jun; 19(3):e440-e451. PubMed ID: 30853347
[TBL] [Abstract][Full Text] [Related]
16. Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer.
Rojas L; Muñiz S; Medina L; Peña J; Acevedo F; Pinto MP; Sanchez C
PLoS One; 2020; 15(2):e0227961. PubMed ID: 32023267
[TBL] [Abstract][Full Text] [Related]
17. A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer.
Dent S; Ammendolea C; Christofides A; Edwards S; Incekol D; Pourmirza B; Kfoury S; Poirier B
Curr Oncol; 2019 Feb; 26(1):e70-e80. PubMed ID: 30853812
[TBL] [Abstract][Full Text] [Related]
18. The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review.
Van den Nest M; Glechner A; Gold M; Gartlehner G
Syst Rev; 2019 Dec; 8(1):321. PubMed ID: 31829250
[TBL] [Abstract][Full Text] [Related]
19. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer.
De Cock E; Pivot X; Hauser N; Verma S; Kritikou P; Millar D; Knoop A
Cancer Med; 2016 Mar; 5(3):389-97. PubMed ID: 26806010
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+ breast cancer patients and financial impact of its use.
Lazaro Cebas A; Cortijo Cascajares S; Pablos Bravo S; Del Puy Goyache Goñi M; Gonzalez Monterrubio G; Perez Cardenas MD; Ferrari Piquero JM
J BUON; 2017; 22(2):334-339. PubMed ID: 28534353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
